Skip to content
value.today

PLX Pharma Inc.

Formerly Grassroots Pharmaceuticals, Inc.

Total raised
$27 M
6 rounds on record
Latest round
$1 M
Feb 2016
First round on record
Jan 2009
Today
Private
No later event on record

Funding rounds

6 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of PLX Pharma Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2016$1 MNo. 6Under $2 million

PLX Pharma Inc.: Raise no. 6, Feb 2016

Investors in this round

27 investors had bought by the notice of Mar 11, 2016: 27 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $2 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Jorden · Executive Officer · CFO, Secretary
  • Gary Mossman · Executive Officer · COO
  • Natasha Giordano · Executive Officer, Director · Director, President, CEO
  • Ron Zimmerman · Executive Officer · Senior Adviser
  • Upendra Marathi · Executive Officer · Senior Vice President
  • Bob Casale · Director
  • Gary Balkema · Director
  • John Hadden II · Director
  • Kirk Calhoun · Director
  • Michael Valentino · Director · Director, Executive Chairman

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Natasha Giordano, President. Source: SEC Form D, newest notice filed Mar 11, 2016. Read the notice at the SEC.

debt, optionsSEC
May 2013$9 MNo. 5$2 to $10 million

PLX Pharma Inc.: Raise no. 5, May 2013

Investors in this round

51 investors had bought by the notice of Jul 8, 2013: 51 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $9 M offered
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Texas

People named in the notice

  • Gary M. Mossman · Executive Officer, Director
  • Ronald R. Zimmerman · Executive Officer, Director
  • Alexander F. Seelenberger · Director
  • David R. Anderson · Director
  • David R. Jorden · Director
  • Lenard M. Lichtenberger · Director
  • Michael F. Valentino · Director
  • Peter F. Mann · Director
  • Tim R. Black · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ronald Zimmerman, President & CEO. Source: SEC Form D, newest notice filed Jul 8, 2013. Read the notice at the SEC.

equitySEC
Apr 2012$8 MNo. 4$2 to $10 million

PLX Pharma Inc.: Raise no. 4, Apr 2012

Investors in this round

33 investors had bought by the notice of Mar 19, 2013: 33 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
$25,000
What was sold
equity, debt
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Texas

People named in the notice

  • Gary M. Mossman · Executive Officer, Director
  • Ronald R. Zimmerman · Executive Officer, Director
  • Alexander F. Seelenberger · Director
  • David R. Anderson · Director
  • David R. Jorden · Director
  • Lenard M. Lichtenberger · Director
  • Michael F. Valentino · Director
  • Tim R. Black · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ronald Zimmerman, President & CEO. Source: SEC Form D, newest notice filed Mar 19, 2013. Read the notice at the SEC.

equity, debtSEC
Jul 2011$3 MNo. 3$2 to $10 million

PLX Pharma Inc.: Raise no. 3, Jul 2011

Investors in this round

22 investors had bought by the notice of Oct 5, 2011: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $7 M offered; $4 M still to sell
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Texas

People named in the notice

  • Gary M. Mossman · Executive Officer, Director
  • Ronald R. Zimmerman · Executive Officer, Director
  • David R. Anderson · Director
  • David R. Jorden · Director
  • Lenard M. Lichtenberger · Director
  • Tim R. Black · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ronald Zimmerman, President & CEO. Source: SEC Form D, newest notice filed Oct 5, 2011. Read the notice at the SEC.

equitySEC
Jul 2010$2 MNo. 2$2 to $10 million

PLX Pharma Inc.: Raise no. 2, Jul 2010

Investors in this round

21 investors had bought by the notice of Aug 9, 2010: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $6 M offered; $4 M still to sell
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Texas

People named in the notice

  • Gary M. Mossman · Executive Officer, Director
  • Ronald R. Zimmerman · Executive Officer, Director
  • David R. Anderson · Director
  • David R. Jorden · Director
  • Lenard M. Lichtenberger · Director
  • Tim R. Black · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ronald R. Zimmerman, President. Source: SEC Form D, newest notice filed Aug 9, 2010. Read the notice at the SEC.

equitySEC
Jan 2009$3 MNo. 1$2 to $10 million

PLX Pharma Inc.: Raise no. 1, Jan 2009

Investors in this round

26 investors had bought by the notice of Jul 9, 2009: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
$24,960
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Texas

People named in the notice

  • David Anderson · Director
  • David Jorden · Director
  • Lenard Lichtenberger · Director
  • Tim Black · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ronald R. Zimmerman, President & CEO. Source: SEC Form D, newest notice filed Jul 9, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • PLX Pharma Inc. had revenue of up to $1 million when it filed its newest notice of a funding round (Mar 2016).

    SEC Form D (revenue range) · Mar 2016

  • Revenue range over time, as stated in its notices: revenue of up to $1 million in 2010; revenue between $1 million and $5 million in 2011; revenue of up to $1 million in 2013; revenue of up to $1 million in 2016.

    SEC Form D (revenue range) · Mar 2016

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Mar 2016

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of PLX Pharma Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 51 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by PLX Pharma Inc.
NameRoleNamed in
David JordenCFO, SecretaryMar 2016
Gary MossmanCOOMar 2016
Natasha GiordanoDirector, President, CEOMar 2016
Ron ZimmermanSenior AdviserMar 2016
Upendra MarathiSenior Vice PresidentMar 2016
Gary M. MossmanExecutive officerJul 2013
Ronald R. ZimmermanExecutive officerJul 2013
Bob CasaleDirectorMar 2016
Gary BalkemaDirectorMar 2016
John Hadden IIDirectorMar 2016
Kirk CalhounDirectorMar 2016
Michael ValentinoDirector, Executive ChairmanMar 2016
Natasha GiordanoDirector, President, CEOMar 2016
Alexander F. SeelenbergerDirectorJul 2013
David R. AndersonDirectorJul 2013
David R. JordenDirectorJul 2013
Gary M. MossmanDirectorJul 2013
Lenard M. LichtenbergerDirectorJul 2013
Michael F. ValentinoDirectorJul 2013
Peter F. MannDirectorJul 2013
Ronald R. ZimmermanDirectorJul 2013
Tim R. BlackDirectorJul 2013
David AndersonDirectorJul 2009
David JordenDirectorJul 2009
Lenard LichtenbergerDirectorJul 2009
Tim BlackDirectorJul 2009